SCHEMBL6498587

SCHEMBL6498587

Cc1ccc(-c2ccc(C(F)(F)F)cc2)c(C(=O)Nc2ccc(N(CCc3cscn3)C(=O)O)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
APOB P04114 2/20 0.44
MTTP P55157 2/20 0.44
GCGR P47871 2/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
KDM4E B2RXH2 1/20 0.39
HSD17B10 Q99714 1/20 0.39
NPC1 O15118 1/20 0.38
GMNN O75496 1/20 0.38
LMNA P02545 1/20 0.38
TP53 P04637 1/20 0.38
CYP1A2 P05177 1/20 0.38
CYP3A4 P08684 1/20 0.38
HTR1A P08908 1/20 0.38
THRB P10828 1/20 0.38
PIM1 P11309 1/20 0.38
CYP2C9 P11712 1/20 0.38
MAOA P21397 1/20 0.38
SLC6A2 P23975 1/20 0.38
HTR2A P28223 1/20 0.38
AGTR1 P30556 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6491092 0.93 CYP3A4 (0.38) GCGRKDM4ENPC1CYP3A4RAB9A
SCHEMBL6491047 0.87 APOB (0.44) APOBMTTPGCGRSMN1; SMN2KDM4E
SCHEMBL6501858 0.87 GCGR (0.43) GCGRSMN1; SMN2KDM4EHSD17B10NPC1
SCHEMBL6488636 0.86 APOB (0.48) APOBMTTPGCGRSMN1; SMN2KDM4E
SCHEMBL6492299 0.85 APOB (0.39) APOBMTTPGCGRSMN1; SMN2KDM4E
SCHEMBL6792786 0.84 KMT2A (0.44) SMN1; SMN2KDM4EHSD17B10NPC1LMNA
SCHEMBL6500248 0.82 APOB (0.45) APOBMTTPKDM4ELMNATP53
SCHEMBL6499324 0.82 POLB (0.41) APOBMTTPGCGRSMN1; SMN2KDM4E
SCHEMBL6500238 0.81 GCGR (0.44) APOBMTTPGCGRSMN1; SMN2KDM4E
SCHEMBL6487631 0.81 NR3C1 (0.41) APOBMTTPGCGRHTTNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 APOB 1/4885MTTP 677/4885GCGR 1784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.